EurekaMag.com logo
+ Translate

The prevention of rifampicin resistance with pyrazinamide


, : The prevention of rifampicin resistance with pyrazinamide. Revue des Maladies Respiratoires 2(4): 205-208

The capacity of pyrazinamide (PZA) to prevent the selection of rifampicin (RMP) resistant mutants were tested by the intravenous inoculation of 160 mice with 2 .times. 106 c.f.u. [colony forming unit] of Mycobacterium tuberculosis, and two weeks later, the treatment of the mice either with 10 mg/kg/day RMP alone or with RMP + PZA 150 mg/kg/day. After three months of treatment, lungs and spleen were culture positive in respectively 95% and 90% of the mice treated with RMP alone and in 37% and 24% of the mice treated by RMP + PZA (p < 10-5). The strains isolated from lungs and spleen were resistant to rifampicin in respectively 87% and 75% of the mice treated with RMP alone and in none of those treated with RMP + PZA.

(PDF 0-2 workdays service)

Accession: 006740640

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Grosset, J.; Truffot-Pernot, C.; Poggi, S.; Lecoeur, H.; Chastang, C., 1985: Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse. The capacity of Pyrazinamide (PZA) to prevent the selection of Rifampicin (RMP) resistant mutants was tested by the intravenous innoculation of 160 mice with 2 X 10(6) c.f.u. of M. tuberculosis, and two weeks later, the treatment of the mice eithe...

Grosset J.; Truffot Pernot C.; Poggi S.; Lecoeur H.; Chastang C., 1985: Prevention of resistance of rifampicin by means of pyrazinamide in experimental tuberculosis in the mouse. Revue des Maladies Respiratoires 2(2): 111

Agrawal, S.; Singh, I.; Kaur, K.J.; Bhade, S.R.; Kaul, C.L.; Panchagnula, R., 2002: Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. Depending on the patient category, tuberculosis requires treatment with 3 to 5 drugs which means that patient's compliance to therapy may not be optimal. To increase patient's adherence to treatment schedules, these drugs can be given as...

Alame-Emane, A.K.; Xu, P.; Pierre-Audigier, C.; Cadet-Daniel, V.; Shen, X.; Sraouia, M.; Siawaya, J.F.Djoba.; Takiff, H.; Gao, Q.; Gicquel, B., 2016: Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern. To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to...

Colebunders, R.; Florence, E., 1998: Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351(9118): 1813-1813

Halsey, N.A.; Coberly, J.S.; Desormeaux, J.; Losikoff, P.; Atkinson, J.; Moulton, L.H.; Contave, M.; Johnson, M.; Davis, H.; Geiter, L.; Johnson, E.; Huebner, R.; Boulos, R.; Chaisson, R.E., 1998: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Background: Tuberculosis is a common complication of HIV-1 infection, especially in developing countries. Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis are needed. Our aim was to test the efficacy of isoniazid ve...

Botha, F.J.; Sirgel, F.A.; Parkin, D.P.; van de Wal, B.W.; Donald, P.R.; Mitchison, D.A., 1996: Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. The early bactericidal activity (EBA) of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater: Mer National) was evaluated in patients with pulmonary tuberculosis who were sputum-positive on microsc...

Pachón-Ibáñez, Mía.E.; Fernández-Cuenca, F.; Docobo-Pérez, F.; Pachón, Jónimo.; Pascual, A., 2006: Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. Objectives: To examine the development of rifampicin resistance in multidrug-resistant Acinetobacter baumannii exposed to rifampicin and the prevention of the appearance of rifampicin-resistant mutants when rifampicin is used in association with i...

Yamamoto, M.; Isoe, K.; Izumi, S.; Fuse, M., 1971: Clinical evaluation of rifampicin in advanced pulmonary tuberculosis resistant to conventional antituberculosis drugs. Combination therapy with rifampicin and pyrazinamide. Kekkaku 46(7): 259-264

Víznerová, A., 1979: Criteria of resistance of some antibiotics and chemotherapeutics for strains of Mycobacterium tuberculosis isolated in Czechoslovakia. Cycloserin, ethionamide, pyrazinamide, rifampicin, and ethambutol. Casopis Lekaru Ceskych 118(8): 240-245